Literature DB >> 21175432

Drug-drug interactions: is there an optimal way to study them?

L D Lewis.   

Abstract

Mesh：

Year:  2010        PMID： 21175432      PMCID： PMC3014060          DOI： 10.1111/j.1365-2125.2010.03829.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  14 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

2.  The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.

Authors:  E J C Dunkley; G K Isbister; D Sibbritt; A H Dawson; I M Whyte
Journal:  QJM       Date:  2003-09

3.  Classifying drug interactions.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

Review 4.  Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Authors:  S-M Huang; R Temple; D C Throckmorton; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

5.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

Authors:  M Tatsumi; K Groshan; R D Blakely; E Richelson
Journal:  Eur J Pharmacol       Date:  1997-12-11       Impact factor: 4.432

6.  Pharmacokinetics of clopidogrel.

Authors:  H Caplain; F Donat; C Gaud; J Necciari
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

7.  Erlotinib and pantoprazole: a relevant interaction or not?

Authors:  Rob Ter Heine; James C Fanggiday; Nienke A G Lankheet; Jos H Beijnen; Monique M L Van Der Westerlaken; Gerald H A Staaks; Mirte M Malingré
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 8.  Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review.

Authors:  Andrew A Monte; Ryan Chuang; Michael Bodmer
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 9.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Authors:  J M Siller-Matula; B Jilma; K Schrör; G Christ; K Huber
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

10.  In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.

Authors:  B A Hamelin; A Bouayad; B Drolet; A Gravel; J Turgeon
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922
View more
  8 in total

1.  Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

Authors:  Joachim Troost; Shinji Tatami; Yasuhiro Tsuda; Michaela Mattheus; Ludwig Mehlburger; Martina Wein; Martin C Michel
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

2.  Drug-drug interactions--bridging the gulf between the bench and the bedside?

Authors:  Y K Loke
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 3.  Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Authors:  Channing J Paller; Penelope A Bradbury; S Percy Ivy; Lesley Seymour; Patricia M LoRusso; Laurence Baker; Larry Rubinstein; Erich Huang; Deborah Collyar; Susan Groshen; Steven Reeves; Lee M Ellis; Daniel J Sargent; Gary L Rosner; Michael L LeBlanc; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2014-08-15       Impact factor: 12.531

4.  The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.

Authors:  Francois Montastruc; Agnès Sommet; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Eric Bui; Haleh Bagheri; Maryse Lapeyre-Mestre; Laurent Schmitt; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2011-11-25       Impact factor: 2.953

5.  Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.

Authors:  Anne Charlotte Danton; François Montastruc; Agnès Sommet; Geneviève Durrieu; Haleh Bagheri; Emmanuelle Bondon-Guitton; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

6.  Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing.

Authors:  Lucreţia Udrescu; Laura Sbârcea; Alexandru Topîrceanu; Alexandru Iovanovici; Ludovic Kurunczi; Paul Bogdan; Mihai Udrescu
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

7.  Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.

Authors:  Alex McKeown; Andrew Turner; Zuzanna Angehrn; Dianne Gove; Amanda Ly; Clementine Nordon; Mia Nelson; Claire Tochel; Brent Mittelstadt; Alex Keenan; Michael Smith; Ilina Singh
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

8.  An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.

Authors:  Robert Shumaker; Min Ren; Jagadeesh Aluri; Corina E Dutcus; Christian Rance; Cixin He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-06       Impact factor: 2.441
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.